Healthgen Biotechnology is uniquely positioned to become a scientific leader in the biopharmaceutical industry. We are dedicated to developing and producing the green and higher security biomedicine for human better lives.

We have achieved scientific excellence through internal research and development, and collaborations with world-renowned biotech and industry leaders. Together we have created a rich product pipeline with innovative products in human therapeutics.

In 2007, Healthgen's scientists developed a breakthrough protein expression technology with unrivaled efficiency. This proprietary technology platform is called OryzExpress. OryzExpress's cost-efficiency and proven commercial scalability make it possible for Healthgen to address unmet and underserved needs in human and animal health by delivering affordable treatments on a global scale.

Healthgen has a number of patented technologies, series of products development and industrialization. Healthgen has successfully made use of the technique to express the recombinant human serum albumin (OsrHSA), recombinant human antitrypsin(rAAT), recombinant trypsin, recombinant insulin-like growth factor(OsrIGF-1) , recombinant acid fibroblast growth factor(OsraFGF) , recombinant basic fibroblast growth factor(OsrbFGF) and other products.